Bristol-Myers Squibb
IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition
April 11, 2016Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV
German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally …
Bristol-Myers Squibb to acquire Padlock Therapeutics for up to $600m
March 23, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Padlock Therapeutics, rheumatoid arthritis
Bristol-Myers Squibb is to acquire Massachusetts-based auto-immune disease specialist Padlock Therapeutics in a deal worth up to $600 million. The …
Delivering successful new drugs
March 1, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, patents, pharma
Pharma companies are struggling with challenges specific to their industry. Patents for many drugs, that had created massive amounts of …
ViiV completes BMS HIV pipeline purchase
February 23, 2016Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV
ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …
UK lung cancer patients get early access to breakthrough BMS drug
February 5, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo
UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …
Europe approves BMS hep C drug for HIV and liver transplant patients
February 1, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, daclatasvir, daklinza
The European Commission has approved the expanded use of Bristol Myers-Squibb’s hepatitis C drug Daklinza (daclatasvir), to include liver transplant …
EMA fast-tracks BMS multiple myeloma drug
February 1, 2016Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, EMA, Empliciti, myeloma
The EMA has recommended granting a marketing authorisation for Bristol Myers-Squibb and AbbVie’s immunotherapy Empliciti for the treatment of multiple myeloma. The …
FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo
January 25, 2016Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer
The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …
NICE ‘yes’ for BMS skin cancer drug Opdivo
January 22, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer
NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …
ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs
December 18, 2015Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare
Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …
NICE rejects BMS cancer drug in draft guidance
December 16, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo
In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …
Bristol-Myers Squibb chooses UCLA as latest research partner
December 14, 2015Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla
Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as …
FDA approves BMS and AbbVie’s Empliciti for multiple myeloma
December 1, 2015Manufacturing and Production, Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Empliciti, FDA, elotuzumab, multiple myeloma
The US healthcare regulator has approved Empliciti – a multiple myeloma treatment co-developed by Bristol-Myers Squibb and AbbVie. The FDA …
BMS and Medicines Patent Pool collaborate to increase Hep C medicine access
November 25, 2015Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C
The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …
Bristol-Myers Squibb in new oncology collaboration
November 25, 2015Research and Development Bristol-Myers Squibb, collaboration, immuno-oncology, investment, venture capital
Bristol-Myers Squibb and European healthcare fund Life Sciences Partners are forming a strategic collaboration to identify breakthrough technologies. The companies …
Latest content
